8-K: Current report filing
Published on February 9, 2007
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
Current
Report Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of
Report (Date of Earliest Event Reported): February 5, 2007
|
LIXTE
BIOTECHNOLOGY HOLDINGS,
INC.
|
|
(Exact
Name of Registrant as Specified in its
Charter)
|
|
Delaware
|
|
(State
or Other Jurisdiction of
Incorporation)
|
|
000-51476
|
20-2903526
|
|
|
(Commission
File Number)
|
(I.R.S.
Employer Identification
No.)
|
|
248
Route 25A, No. 2, East Setauket, New
York
|
11733
|
|
|
(Address
of Principal Executive
Offices)
|
(Zip
Code)
|
|
631-942-7959
|
|
(Registrant’s
Telephone Number, Including Area
Code)
|
|
SRKP
7, INC.
1900
Avenue of the Stars, Los Angeles, CA
90067
|
|
(Former
Name or Former Address, if Changed Since Last
Report)
|
|
Item
1.01
|
Entry
into a Material Agreement
|
On
February 5, 2007 (the “Effective Date”), Lixte Biotechnology Holdings, Inc. (the
“Company”) entered into an agreement (the “Agreement”) with Chem-Master
International, Inc. (“Chem-Master”) pursuant to which Lixte engaged Chem-Master
to synthesize the compound designated LB-1 (as more fully described in the
Agreement) and any other compound synthesized by Chem-Master pursuant to the
Company’s request which has potential use in treating a disease, including,
without limitation, cancers such as glioblastomas.
| Item 3.02 |
Unregistered
Sales of Equity Securities
|
Pursuant
to the Agreement, the Company agreed to grant to Chem-Master a five-year option
to purchase 100,000 shares of the Company’s common stock with an exercise price
of $0.33⅓ per share. Additionally, provided that the Agreement is not terminated
by Lixte without cause or by any party for cause prior to the second anniversary
of the Agreement, the Company agreed to grant to Chem-Master a five year option
to purchase an additional 100,000 shares of the Company’s common stock at $0.33
1/3 share.
| Item 9.01 |
Financial
Statements and Exhibits
|
(c) Exhibits
|
Exhibit
10.1
|
Agreement
between Lixte Biotechnology Holdings, Inc. and Chem-Master International,
Inc.
|
1
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
LIXTE
BIOTECHNOLOGY HOLDINGS, INC.
|
||
| |
|
|
|
Date:
February 6, 2007
|
By: | /s/ John S. Kovach |
|
John
S. Kovach, Chairman of the Board and Chief Executive Officer (principal
executive officer)
|
||
2